ARDX / Ardelyx: XPHOZAH Is No Niche Product

Ardelyx delivered a surprise profit thanks to strong sales of Ibsrela, its first FDA-approved product. The company has also commenced the launch of Xp more_horizontal

Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Caitlin Lowie - Vice President of Corpo more_horizontal

Despite 18 months of rising interest rates from the Fed, the U.S. economy held a steady 4.9% growth rate in Q3, defying the gloomier economic predicti more_horizontal

Ardelyx (ARDX) gets FDA approval for Xphozah to reduce serum phosphorus in adult patients with kidney disease on dialysis as an add-on therapy. The st more_horizontal

Late yesterday, Ardelyx announced that the FDA has approved its first-in-class chronic kidney disease drug Xphozah. The drug adds an important new tre more_horizontal

WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo more_horizontal

Looking at the stock market today is like watching an action movie. One minute the bulls are stampeding and stocks are rising. more_horizontal

Ardelyx (NASDAQ: ARDX ) stock is climbing today after the U.S. Food and Drug Administration (FDA) approved the firm's treatment for excessive phosphat more_horizontal